Welcome to our dedicated page for Journey Medical news (Ticker: DERM), a resource for investors and traders seeking the latest updates and insights on Journey Medical stock.
Journey Medical Corp (DERM) is a commercial-stage pharmaceutical leader specializing in dermatology treatments. This page aggregates official announcements and verified updates about DERM's prescription drug developments, financial performance, and regulatory progress.
Find categorized press releases covering FDA approvals, clinical trial results, partnership agreements, and earnings disclosures. Investors gain streamlined access to strategic updates impacting DERM's position in the $7.3B U.S. dermatology pharmaceuticals market.
Key resources include product launch timelines, research collaboration details, and analysis of DERM's branded/generic medication portfolio. Content is rigorously curated to support informed decision-making without promotional bias.
Bookmark this page for efficient tracking of DERM's advancements in treating acne, rosacea, and other skin conditions through FDA-cleared therapies.
Journey Medical (NASDAQ: DERM) has promoted Ramsey Alloush from General Counsel to Chief Operating Officer (COO), while maintaining his General Counsel position. Alloush, who joined the company in 2020, brings over 15 years of pharmaceutical industry experience.
During his tenure at Journey Medical, Alloush has played a important role in navigating regulatory landscapes, managing financing transactions including the company's 2021 IPO, and overseeing acquisitions and licensing. His background includes experience at the Securities and Exchange Commission and Medicis Pharmaceuticals' Aesthetics Division.
The appointment comes at a strategic time as Journey Medical prepares for the launch of Emrosi™, a new dermatological treatment. The company focuses on marketing FDA-approved prescription pharmaceutical products for dermatological conditions.
Journey Medical (DERM) reported its full-year 2024 financial results, with total revenues of $56.1 million, meeting all financial guidance targets. The company received FDA approval for Emrosi™ (40 mg Minocycline Hydrochloride Modified-Release Capsules) for rosacea treatment in November 2024, with initial distribution and first prescriptions already underway.
Key financial metrics include:
- Product revenue decreased 8% to $55.1 million from $59.7 million in 2023
- Net loss of $(14.7) million, or $(0.72) per share, compared to $(3.9) million in 2023
- Adjusted EBITDA of $0.8 million
- Cash position of $20.3 million as of December 31, 2024
The company's Phase 3 clinical trial results for Emrosi were published in JAMA Dermatology, demonstrating successful achievement of co-primary and secondary endpoints. Full promotion is expected to begin in April 2025.
Journey Medical (NASDAQ: DERM) has announced the launch and first prescriptions of Emrosi™, a 40 mg Minocycline Hydrochloride Modified-Release Capsule treatment for inflammatory lesions of rosacea in adults. The medication, which received FDA approval in November 2024, is now available through specialty pharmacy chains.
Emrosi is the lowest-dose oral minocycline available, featuring a unique 10 mg immediate release and 30 mg extended release formulation. Clinical trials demonstrated superior efficacy compared to Oracea® and placebo while maintaining a comparable safety profile. The most common adverse reaction reported was dyspepsia, occurring in ≥1% of subjects.
Journey Medical (Nasdaq: DERM) has scheduled the release of its year end 2024 financial results on Wednesday, March 26, 2025, after U.S. financial markets close. The commercial-stage pharmaceutical company, which specializes in marketing FDA-approved prescription pharmaceutical products for dermatological conditions, will host a conference call and audio webcast at 4:30 p.m. ET on the same day.
Interested U.S. participants can dial 1-866-777-2509 (domestic) or 1-412-317-5413 (international) to join the conference call. Registration is available at https://dpregister.com/sreg/10197674/feaf5b7354. A live audio webcast will be accessible on the company's website and remain available for approximately 30 days after the call.
Journey Medical (Nasdaq: DERM), a commercial-stage pharmaceutical company focused on marketing FDA-approved dermatological prescription products, has announced its participation in the 37th Annual ROTH Conference from March 16-18, 2025, in Dana Point, California.
President and CEO Claude Maraoui will lead a fireside chat on Tuesday, March 18 at 12:30 p.m. PT and will be available for one-on-one meetings throughout the conference. Investors can access the fireside chat webcast on Journey Medical's website investor section for approximately 30 days following the event.
Journey Medical (NASDAQ: DERM) announced the publication of Phase 3 clinical trial results for Emrosi™ (DFD-29) in JAMA Dermatology. The trials demonstrated superior efficacy of DFD-29 (40 mg Minocycline Hydrochloride Modified-Release Capsules) compared to both Oracea® and placebo in treating rosacea.
Key findings from the MVOR-1 and MVOR-2 trials showed:
- DFD-29 achieved 65.0% and 60.1% IGA treatment success rates respectively
- Significant reduction in inflammatory lesions compared to alternatives
- Superior reduction in erythema versus placebo
- No major safety issues reported
The FDA approved Emrosi™ in November 2024 for treating inflammatory lesions of rosacea in adults, with launch expected in early spring 2025.
Journey Medical (Nasdaq: DERM) announced its participation in the 2025 American Academy of Dermatology Annual Meeting in Orlando, Florida, from March 7-11, 2025. The company will showcase Emrosi™, their newly FDA-approved treatment for inflammatory lesions of rosacea in adults, approved in November 2024.
Emrosi™, featuring 40 mg Minocycline Hydrochloride Modified-Release Capsules (10 mg immediate release and 30 mg extended release), is positioned as the lowest-dose oral minocycline available. According to the company, it demonstrates superior clinical outcomes for rosacea compared to placebo and Oracea® while maintaining a comparable safety profile.
The AAD annual meeting, with over 350 exhibitors and nearly 20,000 attendees, including 10,000+ medical personnel, will provide Journey Medical an opportunity to present their dermatology product portfolio at booth 2181.
Journey Medical (Nasdaq: DERM) has announced a conference call and webcast scheduled for February 5, 2025, at 4:30 p.m. ET to discuss the commercial launch plan for Emrosi™, their newly FDA-approved treatment for inflammatory lesions of rosacea in adults.
The medication, which contains 40 mg Minocycline Hydrochloride in extended-release capsules, was developed in collaboration with Dr. Reddy's Laboratories and received FDA approval in November 2024. The company is currently completing manufacturing of launch quantities for the U.S. market and preparing their dermatology-focused sales force for the product rollout.
The conference call will be accessible via phone (1-866-777-2509 domestic, 1-412-317-5413 international) and webcast through Journey Medical's website. The most common adverse reaction reported in clinical trials was dyspepsia, occurring in ≥1% of subjects treated with Emrosi compared to placebo.
Journey Medical (DERM) reported Q3 2024 financial results with total revenues of $14.6 million, marking a 4% decrease from Q3 2023. The company received FDA approval for Emrosi™, a treatment for inflammatory lesions of rosacea in adults, with launch expected in late Q1 or early Q2 2025. Q3 2024 showed a net loss of $2.4 million ($0.12 per share), compared to net income of $16.8 million in Q3 2023. Gross margin improved to 63.9% from 57.9% year-over-year. The company ended the quarter with $22.5 million in cash and cash equivalents.
Journey Medical (Nasdaq: DERM) has received FDA approval for Emrosi™, a 40 mg minocycline hydrochloride extended-release capsule for treating inflammatory lesions of rosacea in adults. The approval is backed by successful Phase 3 clinical trials where Emrosi demonstrated superior efficacy compared to both Oracea® 40 mg capsules and placebo. The trials met all co-primary and secondary endpoints with no significant safety concerns. Journey Medical plans to launch Emrosi in the U.S. market through its dermatology-focused sales force, with initial supply expected late Q1 or early Q2 2025.
